Global Guillain-Barré Syndrome (GBS) Market, By Type (Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)), Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others), Route of Administration (Oral, Parenteral), Diagnosis (Lumbar Puncture, Electromyography, Nerve Conduction Studies, Others), Treatment (Plasmapheresis, Medication, Physical Therapy, Hydrotherapy, Others), End User (Hospitals and Clinics, Diagnostic Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Guillain-Barré Syndrome (GBS) Market
The guillain-barré syndrome (GBS) market is expected to gain growth at a potential rate of 5.30% in the forecast period of 2021 to 2028. The rise in research and development activities is the factor responsible for the market growth.
Guillain-barre Syndrome is a type of rare immune system disorder. In this condition, the patients’ immune system attacks their nervous system. The causative agents responsible for the guillain-barre syndrome are unknown.
The rapid increase in the prevalence of the guillain-barre syndrome is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rise in the geriatric population and increase in the prevalence of chikungunya are also predictable to enhance the guillain-barré syndrome (GBS) market growth. Furthermore, the rise in the rise in the prevalence of immune disorders like multiple sclerosis and the increase in the research and development are also projected to drive the market growth rate.
In addition, the rapid technological advancement and development in healthcare, rise in the support and funding from government and increase in the approvals of immunoglobulins from regulatory bodies are likely to create various new opportunities that will impact this guillain-barré syndrome (GBS) market growth in the forecast period of 2021 to 2028.
However, the lack of awareness for the disease and absence of any definitive treatment are expected to act as major restraints towards the growth of the guillain-barré syndrome (GBS) market, whereas the low per capita healthcare expenses in the middle and low income countries can challenge the growth of the target market in the above mentioned forecast period.
This guillain-barré syndrome (GBS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the guillain-barré syndrome (GBS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Guillain-Barré Syndrome (GBS) Market Scope and Market Size
Guillain-barré syndrome (GBS) market is segmented on the basis of type, therapeutics, route of administration, diagnosis, treatment, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- The type segment of the guillain-barré syndrome (GBS) market can be segmented into acute inflammatory demyelinating polyradiculoneuropathy (AIDP), miller fisher syndrome (MFS) and acute motor axonal neuropathy (AMAN).
- On the basis of therapeutics, the guillain-barré syndrome (GBS) market can be segmented into intravenous immunoglobulin, plasma exchange and others. Others have further been segmented into analgesics, anticonvulsants, LMWH and others.
- Based on route of administration, the guillain-barré syndrome (GBS) market can be segmented into oral and parenteral.
- On the basis of diagnosis, the guillain-barré syndrome (GBS) market can be segmented into lumbar puncture, electromyography, nerve conduction studies and others. Electromyography has further been segmented into intramuscular electromyography, surface electromyography and others.
- On the basis of treatment, the guillain-barré syndrome (GBS) market can be segmented into plasmapheresis, medication, physical therapy, hydrotherapy and others.
- Based on end user, the guillain-barré syndrome (GBS) market can be segmented into hospitals and clinics, diagnostic centers and others.
- Based on distribution channel, the guillain-barré syndrome (GBS) market can be segmented into hospital pharmacies, retail pharmacies and others.
Guillain-Barré Syndrome (GBS) Market Country Level Analysis
Guillain-barré syndrome (GBS) market is analyzed and market size information is provided by country by type, therapeutics, route of administration, diagnosis, treatment, end user and distribution channel as referenced above.
The countries covered in the guillain-barré syndrome (GBS) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the guillain-barré syndrome (GBS) market due to the strong presence of a well-developed healthcare sector and huge patient population. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the strong presence of huge patient population and developing economies such as India and China.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Guillain-barré syndrome (GBS) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Guillain-Barré Syndrome (GBS) Market Share Analysis
Guillain-barré syndrome (GBS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to guillain-barré syndrome (GBS) market.
The major players covered in the guillain-barré syndrome (GBS) market report are Grifols, S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Mylan N.V., NIHON PHARMACEUTICAL CO., LTD., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Cipla Inc., Akari Therapeutics, Bayer AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Kedrion S.p.A., Baxter and Hansa Biopharma among other domestic and global players. Guillain-barré syndrome (GBS) market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-